Human T Lymphoid Progenitor
Hematologic Malignancy
Assistance Publique - Hôpitaux de ParisCell therapyPhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 73/ 100
Competitive context
116 Active assets in the Hematologic Malignancy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine National Cancer Institute (NCI) | Phase 3 | BB |
FILGRASTIM St. Jude Children's Research Hospital | Phase 2 | BB |
Pegloticase M.D. Anderson Cancer Center | Phase 4 | BB |
Rasburicase M.D. Anderson Cancer Center | Phase 4 | BB |
Fludarabine National Cancer Institute (NCI) | Phase 3 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →